Adaptive gene amplification as an intermediate step in the expansion of virus host range.

Permalink
https://escholarship.org/uc/item/8hf3r09s

Journal
PLoS pathogens, 10(3)

ISSN
1553-7366

Authors
Brennan, Greg
Kitzman, Jacob O
Rothenburg, Stefan
et al.

Publication Date
2014-03-13

DOI
10.1371/journal.ppat.1004002

Peer reviewed
Adaptive Gene Amplification As an Intermediate Step in the Expansion of Virus Host Range

Greg Brennan¹, Jacob O. Kitzman², Stefan Rothenburg³, Jay Shendure², Adam P. Geballe¹,4,5*

¹ Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, ² Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America, ³ Division of Biology, Kansas State University, Manhattan, Kansas, United States of America, ⁴ Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, ⁵ Departments of Microbiology and Medicine, University of Washington, Seattle, Washington, United States of America

Abstract

The majority of recently emerging infectious diseases in humans is due to cross-species pathogen transmissions from animals. To establish a productive infection in new host species, viruses must overcome barriers to replication mediated by diverse and rapidly evolving host restriction factors such as protein kinase R (PKR). Many viral antagonists of these restriction factors are species specific. For example, the rhesus cytomegalovirus PKR antagonist, RhTRS1, inhibits PKR in some African green monkey (AGM) cells, but does not inhibit human or rhesus macaque PKR. To model the evolutionary changes necessary for cross-species transmission, we generated a recombinant vaccinia virus that expresses RhTRS1 in a strain that lacks PKR inhibitors E3L and K3L (VVΔEΔΚ+RhTRS1). Serially passaging VVΔEΔΚ+RhTRS1 in minimally-permissive AGM cells increased viral replication 10- to 100-fold. Notably, adaptation in these AGM cells also improved virus replication 1000- to 10,000-fold in human and rhesus cells. Genetic analyses including deep sequencing revealed amplification of the rhtrs1 locus in the adapted viruses. Supplying additional rhtrs1 in trans confirmed that amplification alone was sufficient to improve VVΔEΔΚ+RhTRS1 replication. Viruses with amplified rhtrs1 completely blocked AGM PKR, but only partially blocked human PKR, consistent with the replication properties of these viruses in AGM and human cells. Finally, in contrast to AGM-adapted viruses, which could be serially propagated in human cells, VVΔEΔΚ+RhTRS1 yielded no progeny virus after only three passages in human cells. Thus, rhtrs1 amplification in a minimally permissive intermediate host was a necessary step, enabling expansion of the virus range to previously nonpermissive hosts. These data support the hypothesis that amplification of a weak viral antagonist may be a general evolutionary mechanism to permit replication in otherwise resistant host species, providing a molecular foothold that could enable further adaptations necessary for efficient replication in the new host.

Introduction

There are at least 868 described zoonotic microbial pathogens, 33% of which are capable of infecting humans to transmit disease [1]. Recent viral zoonoses have led to some of the most devastating and medically relevant outbreaks in modern history, including SARS coronavirus, pandemic influenza, and HIV/AIDS, highlighting the urgent need to understand how viruses adapt to infect new species. At a population level, factors influencing the transmission of zoonotic pathogens to humans include increasing population density, greater contact with wildlife, increased travel, and poor public health infrastructure [2,3]. However, other restriction factors, including protein kinase R (PKR), block the replication of multiple virus families. PKR is activated by binding to double-stranded RNA (dsRNA), a common byproduct of both RNA and DNA virus replication, followed by dimerization and autophosphorylation. Activated PKR then phosphorylates the e-subunit of eukaryotic initiation factor 2 (eIF2α), ultimately arresting translation initiation [9]. In response to the broad and potent barrier to viral infection imposed by PKR, viruses have evolved multiple mechanisms to overcome restriction, including PKR inhibitors [10].

The authors have declared that no competing interests exist.

* E-mail: ageballe@fhcrc.org

Copyright: © 2014 Brennan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NIH (http://www.nih.gov) AI027762 (to APG), NIH 1R21CA160080-01 (to JS), a National Science Foundation (http://www.nsf.gov) Graduate Research Fellowship (to JOK), NIH P20 RR016475 (to SR), and an American Cancer Society (http://www.cancer.org) Postdoctoral Fellowship (to GB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Citation: Brennan G, Kitzman JO, Rothenburg S, Shendure J, Geballe AP (2014) Adaptive Gene Amplification As an Intermediate Step in the Expansion of Virus Host Range. PLoS Pathog 10(3): e1004002. doi:10.1371/journal.ppat.1004002

Editor: Richard C. Condit, University of Florida, United States of America

Received September 12, 2013; Accepted February 1, 2014; Published March 13, 2014

Copyright: © 2014 Brennan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NIH (http://www.nih.gov) AI027762 (to APG), NIH 1R21CA160080-01 (to JS), a National Science Foundation (http://www.nsf.gov) Graduate Research Fellowship (to JOK), NIH P20 RR016475 (to SR), and an American Cancer Society (http://www.cancer.org) Postdoctoral Fellowship (to GB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.
by PKR, most virus families have evolved at least one mechanism to inhibit the PKR pathway [10].

This conflict between host restriction factors and their viral antagonists results in an “arms race” leading to rapid evolution of both sets of genes [11]. The extraordinarily high rate of positive selection (dN/dS) among primate PKR genes reflects the evolutionary pressure on PKR to evade virus antagonists [12,13]. To productively infect new host species, virus antagonists must rapidly adapt to escape these differences in PKR. In the current study, we modeled the process of viral adaptation through an intermediate, minimally permissive host. We experimentally evolved a recombinant vaccinia virus expressing the rhesus cytomegalovirus PKR antagonist rhtrs1 in African green monkey cells expressing RhTRS1-resistant PKR. We demonstrate that amplification of the exogenous rhtrs1 locus was an early adaptation that is sufficient to rescue virus replication in minimally-permissive AGM cells. This amplification of the rhtrs1 locus was also sufficient to expand the species tropism of these viruses, enabling them to infect both human and rhesus cells substantially better than the initial virus. Importantly, rhtrs1 amplification did not occur when the initial virus was passaged through human fibroblasts, suggesting that amplification in AGM cells was a necessary intermediate step to expand the virus host range. Gene amplification is a universal mechanism of rapid adaptation occurring in eukaryotes [14,15], prokaryotes [16], and viruses [17,18], enabling diverse adaptations including evasion of host restriction factors [Reviewed in [19]]. Our results suggest that gene amplification in an intermediate host may be a risk factor for broad cross-species transmission independent of other adaptive events.

Results

Variable inhibition of African green monkey PKR by RhCMV TRS1

The rhesus cytomegalovirus (RhCMV) PKR inhibitor TRS1 (RhTRS1) can block PKR activation and rescue replication of a vaccinia virus mutant lacking the PKR inhibitor E3L (VVΔEΔK+RhTRS1) in several African green monkey (Chlorocebus aethiops, AGM) cell lines [20]. However, we discovered that a recombinant vaccinia virus expressing RhTRS1 and lacking both of the known vaccinia PKR antagonists, E3L and K3L, (VVΔEΔK+RhTRS1) produced 100 to 1000-fold less virus in AGM-derived PRO1190 cells relative to VV-βg (which contains both E3L and K3L) although it replicated almost as efficiently as VV-βg in AGM-derived BSC40 cells (Fig. 1A). Thus, RhTRS1 varies in its ability to support VVΔEΔK replication in different AGM cells.

Figure 1. PKR inhibits VVΔEΔK+RhTRS1 replication in PRO1190 cells. (A) Titers of the indicated viruses produced 48 hpi (MOI = 0.1) of PRO1190 (gray bars) or BSC40 cells (black bars), measured using HFF+TRS1. (B) Immunoblot of lysates of PRO1190 stably transduced with lentiviral vectors expressing control (left) or PKR-specific (right) shRNAs, probed with anti-PKR or anti-actin antibodies. (C) Titers of the indicated viruses 48 hpi (MOI = 0.1) in either PRO1190+ctrl shRNA (grey bars) or PRO1190+PKR shRNA (black bars), measured using BSC40 cells. Results are represented as means ± 1 STD.
doi:10.1371/journal.ppat.1004002.g001

Author Summary

The spread of microbes from animals to humans has been responsible for most recently emerging human infectious diseases, including AIDS, bird flu, and SARS. Therefore, understanding the evolutionary and molecular mechanisms underlying cross-species transmission is of critical importance for public health. After entering a new host cell, the success of a virus depends on its ability to overcome antiviral factors in the cell, such as protein kinase R (PKR). To investigate the process of virus transmission between species, we employed a recombinant vaccinia virus (VVΔEΔK+RhTRS1) expressing the rhesus cytomegalovirus PKR antagonist RhTRS1. This protein inhibits some African green monkey (AGM) PKRs; however, it does not inhibit human or rhesus variants of PKR. Serial passaging VVΔEΔK+RhTRS1 in RhTRS1-resistant AGM cells resulted in rhtrs1 duplication in the viral genome, which improved VVΔEΔK+RhTRS1 replication in AGM cells. Remarkably, rhtrs1 duplication also enhanced virus replication in human and rhesus cells. In contrast, passage of VVΔEΔK+RhTRS1 in human cells, without prior adaptation in AGM cells, did not improve VVΔEΔK+RhTRS1 replication. These results support the hypothesis that amplification of a weak viral antagonist of a host defense protein in one species may enable cross-species transmission into new hosts that are nonpermissive to the initial virus.
This VVÆAK+RhTRS1 replication defect in PRO1190 cells may be due to incomplete inhibition of PKR in these cells by RhTRS1. To test this hypothesis, we generated PRO1190 cells stably expressing either a PKR-specific shRNA (PRO1190-PKR kd), which resulted in a 56% reduction of PKR expression, or a scrambled control shRNA (PRO1190-ctrl kd) (Fig. 1B). Similarly, PKR-specific RT-qPCR demonstrated a 60% reduction in PKR mRNA from PRO1190-PKR kd cells relative to PRO1190-ctrl kd cells (2578 copies or 6503 copies PKR/ng total RNA respectively) but little difference between PRO1190 and PRO1190-ctrl kd cell PKR levels (Fig. S1). In PRO1190-PKR kd cells, VVÆAK+RhTRS1 replication was almost completely rescued to VV-Bg levels (Fig. 1C). We detected a similar increase in VVÆAK+RhTRS1 replication after transiently transfecting PRO1190 cells with a siRNA specific for PKR, but not a control siRNA (data not shown). Sequence analysis of PRO1190 PKR identified three non-synonymous mutations relative to a previously reported AGM PKR (GenBank # EU733254) that is sensitive to RhTRS1 (Fig. S2, [20]). Interestingly, one of these single nucleotide variants is heterozygous in PRO1190 cells, and changes a residue (T577M) that is evolving under positive selection in primates [12]. Although additional studies will be needed to determine whether one or more of these PRO1190 PKR polymorphisms is responsible for increased resistance to RhTRS1, the results shown in Fig. 1 demonstrate that the block to VVÆAK+RhTRS1 replication in PRO1190 cells is mediated by PKR.

Rhtrs1 amplification expands virus tropism to human and rhesus macaque cells

To determine whether VVÆAK+RhTRS1 could adapt to overcome the PKR-mediated block to replication in PRO1190 cells, we utilized a system of experimental evolution. We infected PRO1190 cells with VVÆAK+RhTRS1 at a low multiplicity of infection (MOI = 0.1), 48 hours post infection (hpi) we lysed the infected cells, titred the resulting virus, and infected new PRO1190 cells, repeating this cycle multiple times. After four passages we observed a 10- to 100-fold increase in viral replication that remained stable for at least three subsequent passages in each of three independent lineages (Fig. 2). We next performed a competition assay to assess the relative fitness of the passaged virus in comparison to the initial VVÆAK+RhTRS1 virus. We co-infected PRO1190 cells with either VVÆAK+RhTRS1 or VV-A, both of which express eGFP, and the same competitor, VVÆSL+RhTRS1, which expresses β-gal (MOI = 0.1 for each virus). Virus produced 48 hpi was titered on permissive BSC40 cells and the specific progeny viruses were enumerated by detecting β-gal (VVÆSL+RhTRS1 and eGFP (VVÆAK+RhTRS1 and VV-A) expression in the plaques (Fig. S3). VVÆAK+RhTRS1 replicated ~3-fold better than VVÆSL+RhTRS1, whereas VV-A replicated 290-fold better than VVÆSL+RhTRS1, confirming that serial passage through PRO1190 cells increased the fitness of passaged viruses approximately 100-fold relative to the initial VVÆAK+RhTRS1.

Since the passaged viruses replicated more efficiently in a minimally permissive cell line, we investigated the ability of the passaged viruses to replicate in primary cells from more divergent primates. We have shown that RhTRS1 does not inhibit human or rhesus PKR in the context of VVÆSL [20]. To determine whether the adaptations that evolved during serial passage in PRO1190 cells affected the virus species tropism, we infected human primary foreskin fibroblasts (HFF) or primary rhesus fibroblasts (RF) with VVÆAK+RhTRS1, each of the three passaged virus pools or VV-Bg at an MOI of 0.1 (Fig. 3). As expected, VVÆAK+RhTRS1 replicated poorly and VV-Bg replicated efficiently in each cell type. Remarkably, all three passaged pools replicated between 1000- to 10,000-fold better than VVÆAK+RhTRS1 in both HFF (Fig. 3, center) and RF (Fig. 3, right). For each pfu of VV-A, VV-B and VV-C used to infect the cells, 5.2, 1.9, and 6.3 pfu of progeny emerged from HFF and 40.8, 7.3, and 3.7 emerged from RF, respectively, suggesting that these viruses were sufficiently well adapted to enable continuous propagation in these cells (see below). However, these virus pools still replicated 10- to 100-fold better in PRO1190 than in either human or rhesus cells (Fig. 3, left). Thus, adaptation of VVÆAK+RhTRS1 in minimally permissive AGM fibroblasts also provides a substantial replication benefit in human and rhesus cells expressing distantly related PKR proteins. To elucidate the underlying mechanism for this gain of fitness, we harvested DNA from passage 7 viruses for genetic analyses and then passaged the viruses once more in PRO1190 to generate viral stocks for biochemical and infectivity analyses.

Gene amplification as a mechanism of rapid adaptation in vaccinia virus has been well documented [17,18,21]. To determine whether gene amplification could account for the broadly improved replication of passaged VVÆAK+RhTRS1 we performed paired-end Illumina based deep sequencing (Short Read Archive #SRP03208). Based on read depth, we detected duplication of the rhtrs1 locus in all three passage 7 virus pools but not in VVÆAK+RhTRS1 (Fig. 4A). Each of the passaged pools contained between 1.4 and 1.9 copies of rhtrs1 per genome, although these numbers reflect averages of a heterogeneous population of viral genomes. Confirming this estimate of rhtrs1 copy number, the frequency of reads in which we detected a recombination site near the rhtrs1 locus increased as a percentage of total reads in viruses predicted to have more copies of rhtrs1 (Fig. 4B).

We used PCR to confirm that the rhtrs1 locus was amplified, using externally directed primers specific to rhtrs1 that only amplify a product if there is a tandem duplication of the gene (Fig. S4A). We detected 3 kb products in all three virus pools, and 2.3 kb and 1.8 kb products only in the VV-A virus pool (Fig. S4B). We were unable to obtain enough of the 2.3 kb band for further analysis, but we did characterize the 3 kb and 1.8 kb products by Sanger sequencing. The larger product was identical in all three passaged virus pools, and represents a recombination between the vaccinia virus gene L5R upstream of rhtrs1 with J2R downstream of rhtrs1.
In the smaller product J2R recombined with the neoR gene, which was introduced as a selection marker during construction of VVΔΔΔK+RhTRS1 (Fig. S3C). These two sites represented the predominant recombination sites (85.5% and 2.8% respectively) identified by Illumina deep sequencing. However, we found additional minor recombination sites by Illumina deep sequencing, including a 15 kb duplication in VV-B. The presence of an identical recombination site in all three passaged virus pools suggests that duplication may have been present at a very low frequency in the initial virus population even though we did not detect it in the Illumina sequencing data. Regardless, taken together these data demonstrate that the copy number of rhtrs1 in the viral genome was substantially increased by passage through PRO1190 cells.

Unlike a previous study which identified adaptive point mutations arising after locus expansion [17], we did not detect any point or indel mutations in rhtrs1 in any of the passaged virus pools. However, we identified 13 vaccinia virus gene mutations present at greater than 5% frequency in at least one of the pools (Table 1). All three passaged pools had one or more of four different single nucleotide deletions within the A35R gene at frequencies ranging from 12 to 42%. Transition mutations affecting the A24R and A37R genes were present at >50% frequencies in VV-A and VV-B respectively, but were rare or absent in the other viral pools. None of the other mutations were detected in all three pools or occurred at >50% frequency in any pool, so are unlikely to account for the improved replication of the passaged viruses. However, the presence of these VV gene mutations raised the question of whether the expanded species tropism we observed was due to the VV gene mutations or to rhtrs1 amplification.

If rhtrs1 amplification alone is sufficient for the observed increase in fitness, we reasoned that overexpression of rhtrs1 in trans might rescue VVΔΔΔK+RhTRS1 replication. To investigate this possibility, we stably transduced rhtrs1 into HFF (HFF+RhTRS1), and confirmed RhTRS1 expression by immunoblot (data not shown). We also prepared a control cell line (HFF-LHCX) by transducing the empty vector, LHCX, into HFF. In the control cells, VVΔΔΔK+RhTRS1 replicated approximately 1000-fold less efficiently than VV-βg (Fig. 5A). In HFF+RhTRS1, VVΔΔΔK+RhTRS1 replication increased more than 100-fold. Thus, combined expression of RhTRS1 from genes in both the cell and the infecting virus potentiated VVΔΔΔK+RhTRS1 replication.

Figure 3. Adaptation in minimally-permissive PRO1190 cells expands the species tropism of VVΔΔΔK+RhTRS1. PRO1190 (left), HFF (center), or RF (right) were infected with the indicated viruses (MOI=0.1). Lysates were harvested 48 hpi and titered on BSC40 cells. Data are represented as means ±1 STD.
doi:10.1371/journal.ppat.1004002.g003

Figure 4. Rhtrs1 copy number variation relative to VVΔΔΔK+RhTRS1. (A) Relative read depth of Illumina sequencing reads in the passaged virus pools normalized to VVΔΔΔK+RhTRS1. The graph is centered on the rhtrs1 locus (grey bar). (B) Copy number of RhTRS1 (rescaled so that parental strain = 1) plotted against breakpoint read frequency (per million mapped reads) demonstrates agreement between each independent measure of RhTRS1 duplication.
doi:10.1371/journal.ppat.1004002.g004
| Variant Base(s) | Gene Amplification | Expands Viral Host Range |
|-----------------|---------------------|--------------------------|
| Position | Read Depth | Allele Frequency | Effect | Read Depth | Allele Frequency | Read Depth | Allele Frequency | Read Depth | Allele Frequency | Read Depth | Allele Frequency |
| 39202 | T | TC | F7L | indel | 41 | 4.9% | 43 | 7.0% | 47 | 10.6% | 65 | 6.2% |
| 39203 | A | C | F7L | mis:N33K:aat | 86 | 1.7% | 111 | 10.8% | 124 | 1.6% | 190 | 3.7% |
| 92103 | G | T | J6R | mis:G268C:ggc | 148 | 0.0% | 118 | 0.0% | 132 | 31.1% | 136 | 0.0% |
| 142469 | C | T | A24R | mis:T1121M:acg | . | . | 64 | 0.0% | 100 | 73.0% | 104 | 0.0% |
| 146037 | T | TAA | A31R | indel | 70 | 0.0% | 96 | 17.7% | 94 | 0.0% | 123 | 1.7% |
| 148449 | TA | T | A35R | indel | 117 | 0.0% | 118 | 0.0% | 132 | 0.0% | 124 | 0.0% |
| 148499 | CA | C | A35R | indel | 123 | 0.0% | 118 | 0.0% | 132 | 0.0% | 149 | 0.0% |
| 148601 | CTA | C | A35R | indel | 123 | 0.0% | 118 | 0.0% | 132 | 0.0% | 149 | 0.0% |
| 149912 | G | A | A37R | mis:S116N:agc | 123 | 0.0% | 118 | 0.0% | 106 | 50.9% | 141 | 2.1% |
| 150258 | C | CA | A ORF O | indel | 74 | 0.0% | 138 | 0.7% | 125 | 2.4% | 151 | 2.4% |
| 178360 | TA | T | NA | N/A* | 45 | 0.0% | 79 | 5.1% | 75 | 0.0% | 125 | 2.4% |

* Not annotated.

**Table 1.** Mutations identified in VVΔAEK+RhTRS1 and passaged viruses relative to vaccinia virus (strain Copenhagen).

Supporting the hypothesis that *rhtrs1* amplification alone is sufficient to expand the species tropism of VVΔAEK+RhTRS1.

Although *rhtrs1* amplification provided a substantial growth benefit in HFF and RF, the passaged viruses still replicated 100- to 1000-fold less efficiently than VV-βg (Fig. 3). To determine whether this incomplete rescue in HFF was due to incomplete PKR inhibition or represented a second block to replication, we infected HFF stably transduced with either a PKR specific shRNA (HHF-PKR kd) that reduces PKR expression > 95%, or a non-specific shRNA (HHF-ctrl kd) [22]. Knocking down PKR increased VVΔAEK+RhTRS1 replication ~1000-fold, indicating that PKR is a major barrier to replication in these cells (Fig. 5B).

All three passaged virus pools replicated ~10-fold better in HHF-PKR kd cells than in HFF-ctrl kd cells, suggesting that *rhtrs1* amplification, which fully inhibits PRO1190 PKR, only partially inhibits human PKR. However, these viruses all replicated ~10-fold less well than VV-βg in the HFF-PKR kd cells. This remaining replication defect may be due to incomplete PKR knockdown in these cells [20], although it is also possible that an additional host factor inhibits VVΔAEK+RhTRS1 replication in HFF.

**RhTRS1 inhibits the PKR pathway after autophosphorylation in multiple species**

Unlike many known PKR inhibitors that block PKR phosphorylation [10,23], RhTRS1 inhibits the PKR pathway after PKR phosphorylation but prior to eIF2α phosphorylation [20]. However, it is possible that RhTRS1 amplification inhibits PKR through an alternative mechanism, such as dsRNA sequestration. To determine whether *rhtrs1* amplification altered the mechanism of PKR inhibition, we infected PRO1190 with VV-βg, VVΔAEK, VVΔAEK+RhTRS1, and VV-Δ at an MOI of 3, and collected cell lysates 24 hpi. 35S metabolic labeling demonstrated that VVΔAEK+RhTRS1 expressed vaccinia virus proteins in PRO1190 cells, though in much lower quantities than VV-βg, consistent with the former virus being unable to inhibit PKR completely (Fig. 6, top left panel). In contrast, VV-Δ produced abundant vaccinia virus proteins, similar to VV-βg, confirming that this virus efficiently inhibits the PKR pathway.

We used immunoblot analyses to determine the stage of the PKR pathway inhibited by each virus (Fig. 6, lower panels). RhTRS1 expression was noticeably higher in the VV-Δ infected cells compared to those infected with VVΔAEK+RhTRS1, consistent with the better replication of VV-Δ in PRO1190 cells (Fig. 6, lanes 4 and 5). PKR phosphorylation was elevated in all virus infected cells except VV-βg, consistent with our previous report [20] that even when RhTRS1 blocks the PKR pathway, it does not block PKR autophosphorylation (Fig. 6, lanes 3–5). Phospho-eIF2α levels in VVΔAEK+RhTRS1 infected cells were intermediate between mock and VVΔAE3L infected PRO1190 cells, suggesting that a single RhTRS1 gene weakly inhibits the PKR pathway (Fig. 6, lane 4). Infection with VV-Δ resulted in low levels of eIF2α phosphorylation, similar to that detected in VV-βg infected PRO1190 cells (Fig. 6, compare lanes 2 and 5), indicating that RhTRS1 amplification is sufficient to completely inhibit PKR-mediated translational shutdown at a stage after PKR phosphorylation. Together, these data suggest that PKR-mediated pressure in PRO1190 cells selected for rapid amplification of the *rhtrs1* locus, and that this amplification was sufficient to enable the virus to block PKR-mediated defenses in PRO1190 cells without altering the mechanism of RhTRS1-mediated PKR inhibition.

In previous studies, RhTRS1 alone was insufficient to inhibit human PKR [20]; however, the passaged viruses reported here replicate substantially better in HFF than VVΔAEK+RhTRS1,
suggesting that amplification of \( \text{rhtrs1} \) is able to inhibit PKR at least partially in these cells. To test this hypothesis and determine whether the mechanism of PKR inhibition was the same in HFF as it is in PRO1190, we infected HFF (MOI = 3) and prepared cell lysates 24 hpi. In contrast to infection of PRO1190 cells, infection of HFF with VVA\( \Delta \text{EAK+RhTRS1} \) resulted in nearly complete shut off of protein synthesis by 24 hpi (Fig. 6, top right panel) and produced only trace amounts of RhTRS1. Compared to VVA\( \Delta \text{EAK+RhTRS1} \), VV-A infection of HFF resulted in detectable, though still low overall levels of \(^{35}\)S labeled proteins, and much more RhTRS1 (Fig. 6, lanes 9 and 10). PKR phosphorylation and eIF2a phosphorylation were elevated after infection with both VVA\( \Delta \text{EAK+RhTRS1} \) and VV-A compared to mock or VV-\( \beta \)-g controls (Fig. 6, compare lane 9 to lanes 6 and 7). These data suggest that a single copy of \( \text{rhtrs1} \) was insufficient to inhibit the translational shutoff mediated by human PKR, but amplification of this weak antagonist resulted in partial inhibition of human PKR allowing enough protein synthesis to support a modest level of virus replication.

**RhTRS1 amplification in PRO1190 is a necessary intermediate for VVA\( \Delta \text{EAK+RhTRS1} \) replication in HFF**

Because selection in AGM cells resulted in a broad expansion of viral species tropism, we investigated whether passage of VVA\( \Delta \text{EAK+RhTRS1} \) directly in HFF would similarly select for mutants, such as \( \text{rhtrs1} \) amplification, that improved replication in HFF. We therefore serially infected PRO1190 cells and HFF with VVA\( \Delta \text{EAK+RhTRS1} \) in parallel (Fig. 7). In PRO1190 cells, viral fitness again increased after four passages. In contrast, virus replication was strongly inhibited in HFF, and we were unable to detect any viral replication after three rounds of infection in all three pools. These data suggest that, under these experimental conditions, adaptation in PRO1190 cells was a necessary intermediate step for improved replication in HFF.

Finally, we evaluated whether the improved replication of the viruses that had been passaged in PRO1190 cells was sufficient to enable stable propagation in HFF. We therefore serially infected HFF with VV-A, VV-B and VV-C at low multiplicity of infection (MOI = 0.1 at each passage). We were able to propagate these viruses in HFF for at least four passages. Moreover, replication increased between 5- to 14-fold after only two passages, suggesting further adaptation occurred in HFF cells (Fig. 7B). To define mutations that may have evolved during serial passage in HFF, we performed paired-end Illumina based deep sequencing on viral DNA isolated after the fourth round of passage in HFF. Again, we did not find any mutations in \( \text{rhtrs1} \); however, we detected an average \( \text{rhtrs1} \) copy number of 1.7, 2.8, and 2.7 for the virus pools derived from VV-A, VV-B and VV-C, respectively, representing an average expansion of the \( \text{rhtrs1} \) locus by approximately one additional copy relative to the PRO1190-adapted viruses. In addition, two VV gene mutations (in F7L [indel] and J6R) that arose during PRO1190 adaptation were lost after HFF adaptation, and two new mutations (in F7L [missense] and H4L) of uncertain significance appeared during HFF adaptation (Table S3). Taken together, our study suggests the hypothesis that gene amplification acts broadly to increase replication in a variety of hosts, and may provide a molecular foothold that allows for continued species-specific adaptation of the virus in more resistant hosts.

**Discussion**

Cross-species pathogen transmissions have been responsible for more than 60% of all emerging infectious diseases in humans during the past 70 years [24]. Human immunodeficiency viruses, avian influenza viruses, and the recently described Middle East respiratory syndrome coronavirus exemplify the ongoing threat and potential of animal viruses to spread to and among humans, highlighting the urgent need to understand the mechanisms underlying cross-species transmission and adaptation to new hosts. One such mechanism, genetic locus amplification in response to selective pressure, has been observed in both viruses and bacteria [16–18,21]. Here we demonstrate that amplification of the exogenous gene \( \text{rhtrs1} \) is sufficient to block potent PKR-mediated inhibition and improve VVA\( \Delta \text{EAK+RhTRS1} \) replication in AGM-derived PRO1190 cells. This adaptation also expanded the species tropism of the virus, enabling markedly improved replication in otherwise resistant human and rhesus monkey cells. Importantly, VVA\( \Delta \text{EAK+RhTRS1} \) failed to replicate in HFF to a level sufficient to sustain transmission upon serial passage, demonstrating that adaptation in PRO1190 was a critical intermediate step to expand the viral species tropism. Thus, the process of adaptation in one host may increase the likelihood of virus transmission to a variety of divergent species.

Under PKR-mediated selective pressure, the \( \text{rhtrs1} \) locus amplified during serial passage of VVA\( \Delta \text{EAK+RhTRS1} \) in minimally permissive PRO1190 cells (Fig. 4). It is not clear whether the initial duplication(s) occurred during preparation of the VVA\( \Delta \text{EAK+RhTRS1} \) stock in BSC40 cells or during the first
few passages in the PRO1190 cells. The observation of a faint PCR product from the starting virus, VV\(\text{D}E\text{D}\text{K}+\text{RhTRS1}\) using outward directed \textit{rhtrs1} primers in one of three experiments (Fig. S4), and the detection of an identical recombination break point in all 3 independently passaged virus pools suggest the amplification may have been present at a very low level in the starting virus. However, amplification of the locus in VV\(\text{D}E\text{D}\text{K}+\text{RhTRS1}\) occurred below the level of Illumina deep sequencing detection (Fig. 4), supporting the idea that if \textit{rhtrs1} duplications are present they are rare in the initial VV\(\text{D}E\text{D}\text{K}+\text{RhTRS1}\) stock. Additionally, we detected recombination between J2R and \textit{neoR} (Fig. S4) only in the VV-A pool, suggesting that recombination events did arise during serial passage. Regardless of when they arose, amplifications of the \textit{rhtrs1} locus were substantially enriched during virus passage under selective pressure (Figs. 2 and 4). A previous study demonstrated amplification of K3L as an adaptive mechanism against human PKR with strikingly similar kinetics to the current study [17]. Together, these two studies support the hypothesis that preexisting or frequently arising de novo gene duplications enable vaccinia virus to adapt rapidly to selective conditions imposed by relatively resistant host restriction factors.

The “accordion hypothesis” of rapid evolution posits that gene amplification provides a replication benefit to the virus and those extra copies of a weak viral antagonist of host defenses provide additional templates to acquire potentially adaptive mutations. Indeed, Elde, et al. detected such an adaptive mutation in K3L (H47R), apparently arising after amplification of the locus [17]. Therefore, we were surprised that no mutations arose in \textit{rhtrs1}, although it may be that additional rounds of replication would reveal such mutations. We did, however, detect 13 mutations in endogenous vaccinia virus genes that occurred at \(>5\)% frequency (Fig. 4). While our data suggest that none of these mutations are necessary to expand the species tropism of VV\(\text{D}E\text{D}\text{K}+\text{RhTRS1}\) (Fig. 5), we have not ruled out the possibility that they may provide some replication benefit. The presence of mutations in A24R, A35R, and A37R are the most intriguing, as they were either present at \(>50\)% frequency in one pool (A24R and A37R) or detectable in all three pools (A35R). None of these genes has been previously implicated as a PKR antagonist. A37R is conserved across multiple poxvirus families (http://www.poxvirus.org), but its function is unknown. A24R is a subunit of RNA polymerase. If the mutation we identified acts like some other reported RNA polymerase mutations to decrease transcription elongation [25,26], this mutation might result in less dsRNA production and therefore less PKR activation. A35R is a gene of unknown biochemical function that may be involved in evasion of the adaptive immune response [27,28]. All three passaged virus pools contained nucleotide deletions in A35R at greater than 10% frequency. A35R orthologs are conserved across most poxviruses but, intriguingly, variola virus contains a truncation in its A35R.

Figure 6. Effects of RhTRS1 overexpression on the PKR pathway in PRO1190 or HFF. PRO1190 (left) or HFF (right) were infected with the indicated viruses (MOI = 3) for 24 hpi. Proteins were labeled with \textsuperscript{35}S-methionine for 1 h and cell lysates were analyzed by autoradiography (top panel) or immunoblotting with the indicated antibodies (bottom panels). doi:10.1371/journal.ppat.1004002.g006
gene, demonstrating that similar truncations have evolved in the past. Further studies are underway to evaluate the potential contributions of these mutations to viral replication.

Consistent with previous studies of RhTRS1 in other AGM cell types [20], PKR, but not eIF2α, was phosphorylated in PRO1190 cells infected with VV-A. Thus, the improved replication of the passaged virus pools in PRO1190 cells was likely due to enhancement of the basic RhTRS1-mediated inhibition of PKR, and not due to another mechanism, such as dsRNA sequestration or reduction in the abundance of dsRNA. VVAΔΔK+RhTRS1 infected PRO1190 cells had phospho-eIF2α levels lower than that found in VVAΔ3L infected cells (Fig. 6, lanes 3 and 4), suggesting that even just a single copy of rhtrs1 is able to inhibit PKR function to a small degree, but amplification of the locus appears to be needed to express enough RhTRS1 to inhibit eIF2α phosphorylation potently and enable efficient viral replication. It is also possible that elevated expression of RhTRS1 is necessary to block another activity of PKR, such as autophagy or inflammasome responses [29–31] that might aid in replication.

Adaptation of VVAΔΔK+RhTRS1 to PRO1190 cells provided a substantial replication advantage in both human and rhesus monkey fibroblasts. Although VV-A replicated to much higher titers and expressed more RhTRS1 than VVAΔΔK+RhTRS1 in HFF, 35S metabolic labeling revealed relatively low protein synthesis rates and eIF2α phosphorylation was still elevated after VV-A infection compared to VV-βg. A substantial proportion of the block to VV-A replication in HFF is still mediated by PKR despite RhTRS1 overexpression (Fig. 5B), suggesting that further adaptation in HFF may be necessary to block the PKR pathway in HFF completely. These results indicate that RhTRS1 overexpression blocks human PKR incompletely. Nonetheless, viruses that had adapted by initial passage in PRO1190s replicated in HFF at a level sufficient to enable sustained passage in HFF (Fig. 5B). Furthermore, these PRO1190-adapted viruses acquired additional changes as a result of serial passage in HFF, although the biological relevance of these changes is currently unclear.

Combined with the observation that serial passage of VVAΔΔK+RhTRS1 in HFF failed to generate any adapted viruses (Fig. 7A), these data suggest that adaptation of rhtrs1 in minimally permissive PRO1190 cells was a critical intermediate step in the generation of a virus with broadened species tropism.

Cross-species pathogen transmission is an important source of emerging infections worldwide. Our study illustrates that gene amplification of a weak viral antagonist of PKR can broaden the host range of vaccinia virus. The presence of gene families in other large DNA viruses, e.g. the cytomegalovirus US22 family, of which rhtrs1 is a member, provides indirect evidence that episodes of locus amplification have also occurred in other viruses. Adaptation of a viral antagonist through non-synonymous mutations has the potential to confer a species-specific advantage for the virus in a specific host. In contrast, gene amplification and subsequent over-expression of the antagonist is more likely to increase protein activity through mass action effects in a variety of hosts. Thus, gene amplification may be a common evolutionary strategy employed by large DNA viruses, permitting modest replication in otherwise resistant host species and providing a molecular foothold that enables further adaptations necessary for more efficient replication and spread in the new host.

**Materials and Methods**

**Viruses and cell culture**

AGM fibroblasts [PRO1190, Coriell Institute for Medical Research] human foreskin fibroblasts (HFF), rhesus fibroblasts (RF), BSC40 and HeLa cells, and derivative cell lines were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% NuSerum (BD Biosciences) as previously described [32]. At times, PRO1190 cell lines were also propagated in Minimal Essential Medium with 20% fetal calf serum and antibiotics to enable more rapid growth. PRO1190 cells were transduced with a nonsilencing control or PKR-targeting shRNA lentiviral vectors (Open Biosystems, catalogue numbers RHS4430-98819555 and RHS4346, respectively) and selected in puromycin (5 μg/ml to...
generate PRO1190-ctrl k/d and PRO1190-PKR k/d cells. pEQ1364 was constructed by moving the RhTRS1 gene, with a C-terminal biotinylation signal and 6x-His tag, as a HindIII/Pmel fragment from pEQ1215 [20] into the HindIII/HpaI sites of pLHCCX (Clontech Laboratories, Inc.). HF-LHCCX and HFF+RhTRS1 were produced by transducing HFF with retroviral vectors made using LHCCX and pEQ1364, respectively and selecting with hygromycin B (100 µg/ml).

Vaccinia virus (VV) Copenhagen strain (VC2) [33] and VVAE3L [34], both obtained from Bertram Jacobs (Arizona State University), and VV-βg (VC2-LaCZ in [20]) were propagated and tiered in BSC40 cells. VC-R2 (VVΔEAKΔK3L) was constructed by replacing the E3L gene in the K3L-deleted VACV Vp872 strain (K3L in VC2 background, provided by Bertram Jacobs) [35] by homologous recombination. The 518 bp 5’ arm was created by PCR amplification of VC2 DNA with primers C15 (5’-GATTACGGA-TACTACGGCACCAGG-3’×C16 (5’-TTTTAGAGAAGACTA-ACACAAACCAGC-3’). The 512 bp 3’ arm was created by PCR amplification of VC2 DNA with primers C19 (5’-GTGTAG-TAACGTAAGCGAGCTCGCTAGCCTTCTTATGTTAAGCTACGAGCTCGGTACCTTCTAGTTAATAA-3’) and C20 (5’-CTAAGCTAGCGAGCTCGGTACCTTCTAGTTAATAA-3’) in VC-R2 is under the control of the endogenous E3L promoter.

**Experimental evolution of VVΔEAK+RhTRS1**

For every round of infection, triplicate confluent 10 cm dishes (Figure 2) or 6-well plates (Figure 7) of PRO1190 or HFF were infected with VVΔEAK+RhTRS1 (MOI = 0.1). Two days post-infection, cells were collected, pelleted and resuspended in 1 mL DMEM+10% NuSerum. After three freeze/thaw cycles, virus titers were determined on BSC40 by plaque assays and used for the next round of infection. If insufficient virus was produced to infect cells at MOI = 0.1, the entire volume of virus lysate was used in the subsequent round of infection.

Vaccinia virus DNA from passage 7 in PRO1190 (Figure 2) or passage 4 in HFF (Figure 7 right) viruses was purified from infected cell cytoplasmic extracts for genetic analyses described below [39]. The passage 7 pools were further expanded (passage 8) in PRO1190 for use in virologic assays.

**Competition assay**

PRO1190 cells were co-infected with 0.1 MOI of either VVΔEAK+RhTRS1 or VV-ΔE to generate plasmid pEQ1233 [20] into the thymidine kinase (TK) locus of VVΔEAK. Recombinant virus was plaque-purified three times and titered in HFF using 10^6 PFU/ml. After three freeze/thaw cycles, virus titers were determined on BSC40 by plaque assays. VVΔEAK+RhTRS1 plaques were detected with the β-gal substrate ImaGene Red C12RG following the manufacturer’s directions (Life Technologies). Plaques were imaged on a Typhoon Trio imager (eGFP - 488 nm excitation, 520 BP 40 filter; ImaGene Red - 532 nm excitation, 580 BP 30 filter) at 50 µm/pixel resolution, and classified as GFP+, ImaGene Red+ or double positive using ImageJ software (http://rsb.info.nih.gov/ij/).

**Genomic analyses**

**Externally directed PCR.** Externally directed oligonucleotides were designed that bind near the 5’ or 3’ end of RhTRS1 (#915: 5’TGTGGGAGGATGCATTGC; #916: 5’GACTACAATCCCGATTG). High-fidelity PCR was performed with 100 ng of purified virus DNA following the manufacturer’s directions (Phusion, Thermo Scientific). Reactions were pulsed at 98°C×30 s followed by 25 cycles of 98°C×10 s, 65°C×30 s, 72°C×3 min. Amplification products were gel-purified and cloned using the Stratataclone PCR cloning kit (Agilent) following the manufacturer’s suggested protocol. Recombination sites were identified by Sanger sequencing of these products.

**Library preparation and sequencing.** From each viral pool, 75 ng of viral DNA was sheared and ligated to adaptors by transposition using the Nextera kit (Epicentre), following the manufacturer’s direction with several modifications: transposition was performed in 20 ul volume using 0.1 µl Nextera transposase enzyme and “HMW” reaction buffer at final 1X. Transposition was carried out for 10 minutes at 55°C, after which sheared, adaptor-ligated templates were transferred directly to PCR reactions for amplification. In addition, PCR incorporated a single-sample barcode tag on the reverse primer. Amplified libraries were pooled and cleaned using Ampure beads (Beckman Coulter) at a 1:8.1 ratio of beads to input. The pooled libraries were sequenced on an Illumina HiSeq 2000 instrument (Illumina) using 101-bp forward and reverse reads with a 9-bp index to read the per-sample barcode.

**Sequence analysis.** De novo assembly guided by the Vaccinia virus Copenhagen genome (GenBank #M535027) was used to construct a reference assembly sequence for
VVΔΔAK+RhTRS1 (Tables S1 and S2). Shotgun reads from the parental virus were assembled to contigs using ABySS 1.3.4 [40]; parental virus reads were then realigned against the resulting assembly contigs using bwa 0.6.1 [41]. Discrepancies between reads and contigs, reflecting *de novo* assembly errors, were corrected in the contigs following manual examination, and contigs were ordered and concatenated by comparison to the Copenhagen sequence.

Reads from each evolved viral pool were aligned to the parental reference genome, and single-base and short-indel variants were called using the Genome Analysis Toolkit [42]. Custom scripts were used to determine the allele frequency (fraction reads supporting variant allele out of all aligned reads at a given site) for all variants found in any sample. Copy number was estimated by counting the depth of read coverage within sliding windows of 100 bp, correcting for effects of differences in G+C composition, and dividing by the parental strain read depth. Everted reads at duplication breakpoints were identified using bwasw [43] and custom scripts, as previously described [17].

**Immunoblot analyses**

Cells were mock infected or infected with vaccinia viruses (MOI = 3). One day postinfection, the cells were lysed in 2% sodium dodecyl sulfate (SDS). Equivalent amounts of the lysates were separated on 10% SDS-polyacrylamide gels, transferred to polyvinylidene difluoride (PVDF) membranes, and probed with one of the following antibodies: PKR (sc-6282; Santa Cruz Biotechnology, Inc.), phospho-PKR (T446; 1120-1; Epitomics), eIF2α or phospho-eIF2α (Ser51) antibody (both from Cell Signaling Technology, catalog numbers 9722 and 9721, respectively), TRS1 α999 [37], or actin (A2066; Sigma). All purchased antibodies were used according to the manufacturer’s recommendations. Proteins were detected using the Western Star chemiluminescent detection system (Applied Biosystems) according to the manufacturer’s recommendations. Densitometry measurements were performed using ImageJ.

**RT-qPCR**

Total RNA was extracted from PRO1190, PRO1190-ctrl kd, and PRO1190-PKR kd cells with TRIzol reagent following the manufacturer’s protocol (Invitrogen), and 1 ng of total RNA was assayed per reaction. The standard curve was generated from 10-fold serial dilutions of a PRO1190 PKR containing plasmid (described above in PRO1190 PKR sequence analysis, pEQ1334) diluted in 200 pg/μL salmon sperm DNA. All samples were amplified in triplicate using the GoTaq 1-step RT-qPCR kit following the manufacturer’s protocol (Promega) using PKR specific primers (#1063: 5’-CAGAGAAATTGCAGGAAAGACG; #1064: 5’-ATCAGATAGACCCTATGTA). RT-qPCR was performed on a Rotor-Gene Q thermocycler (Qiagen) with 40 cycles of 95°C for 15 s, 60°C for 30 s. Raw data was analyzed using the included Rotor-Gene Q series software using the automatic cycle threshold (Ct) setting for assigning baseline and threshold for Ct determination. Nonlinear regression analysis to determine PKR copy number in the experimental samples was performed in GraphPad Prism 6.

**Metabolic labeling**

PRO1190 and HFF cells were mock infected or infected with the indicated viruses (MOI = 3). At 24 hpi, the cells were labeled for 1 h with 100 μCi/ml L-[35S]methionine/L-[35S]cysteine (EasyTag express protein labeling mix; PerkinElmer) in medium lacking methionine and cysteine. The cells were then lysed in 2% SDS. Equivalent amounts of protein from each sample were separated on 10% SDS-polyacrylamide gels, dried, and visualized by autoradiography.

**Supporting Information**

**Figure S1** RT-qPCR analysis of PKR copy number in PRO1190-derived cell lines. RT-qPCR was performed on serial 10-fold dilutions of a PKR containing plasmid from 106 to 103 copies of PKR to generate a standard curve (top). Data are represented as the mean ±/− standard deviation. PKR copy number/ng total RNA was interpolated from this standard curve for PRO1190, PRO1190-ctrl kd, and PRO1190-PKR kd cells (bottom). Relative to PRO1190 cells, PRO1190-ctrl kd cells expressed slightly less PKR (20% decrease), while PRO1190-PKR kd cells had a 69% decrease in PKR expression. Similarly, PRO1190-PKR kd cells expressed 60% less PKR than PKR-ctrl kd cells, consistent with Fig. 1B. (TIF)

**Figure S2** Amino acid alignment of African green monkey, human, and rhesus PKR. Predicted PKR amino acid sequences from AGM (PRO1190T1610 and EU733254), rhesus macaque (GenBank# EU733261), and human (GenBank # NM001135651) were aligned using CLUSTAL W (1.83) [38]. We identified three non-synonymous amino acid differences (grey or green highlighted residues) between the two AGM alleles. One of these differences is at a site that is evolving under positive selection in primates (green highlighted residue) [12]. Relative to PRO1190 PKR, rhesus and human PKR are 90.8% and 83.2% identical at the amino acid level, respectively. (TIF)

**Figure S3** Increased fitness of VV-A compared to VVΔΔAK+RhTRS1 assessed by indirect competition assay. PRO1190 cells were co-infected with either VVΔΔAK+RhTRS1 or VV-A (MOI = 0.1) and the same competitor virus, VVΔΔE3L+RhTRS1 (MOI = 0.1). Two days post-infection viral progeny were collected and titered on BSC40 cells. (A) Representative Typhoon image of virus tier plates produced by infection with VVΔΔAK+RhTRS1 in combination with either VVΔΔAK+RhTRS1 (top panels) or VV-A (bottom panels). (B) Plaques were scored for eGFP expression (VVΔΔAK+RhTRS1 or VV-A), β-gal expression (VVΔΔE3L+RhTRS1 or VV-A), and E3L (top panels) or RhTRS1 (bottom panels). Recombination sites occur (middle) after nt 84267 (J2R) and before nt 83200 (K). PCR products amplified by externally directed primers (grey arrows) and internally directed PCR revealed enrichment of tandem duplications will produce an amplification product. (B) Externally directed oligonucleotides (grey arrows) directed PCR. Externally directed oligonucleotides (grey arrows) were designed to bind to the ends of *rhtrs1* (white). Only tandem duplications will produce an amplification product. (B) Externally directed PCR revealed enrichment of *rhtrs1* amplification products in the passaged virus pools. (C) Schematic of the initial *rhtrs1* locus in VVΔΔAK+RhTRS1 (top), and the predominant recombination sites identified in all three passaged viruses (middle), or in VV-A alone (bottom). Vaccinia virus genes are colored green or blue, and exogenous sequences are colored dark red (*rhtrs1*) or brown (*neor*). PCR products amplified by externally directed primers (black bars), the duplicated sequence (grey boxes), and the recombination sites (red arrowheads), are indicated. Recombination sites occur (middle) after nt 84267 (*J2R*) and before nt 83200 (*L5R*) relative to the reference vaccinia virus. Copenhagen strain...
Table S1 Genomic coordinates for regions in whole genome alignment between Vaccinia copenhagen reference (GenBank M53027.1) and parental genome (VVAEAK+RhTRS1) genome sequenced here, as determined by MUMmer 3.2.1 [44].

(DOCX)

Table S2 Substitution and short indel variants (<10 bp) present in parental genome (VVAEAK+RhTRS1) as compared to Vaccinia Copenhagen genome (excluding any in the inverted terminal repeat regions). Predicted effects upon protein coding genes as annotated in the Copenhagen reference are listed, with more than one line per variant indicating effects upon multiple overlapping gene models.

(DOCX)

References

1. Yamada A (2004) [Zoonoses]. Uirusu 54: 17–22.

2. Mahy BW (2000) The global threat of emerging infectious diseases. Isr Med Assoc J 2 Suppl: 23–26.

3. Brandt RG, Leighton FA, Fischer JR, Artois M, Morner T, et al. (2004) The role of wildlife in emerging and re-emerging zoonoses. Rev Sci Tech 23: 497–511.

4. Parrish CR, Holmes EC, Morens DM, Park EG, Burke DS, et al. (2008) Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev 72: 457–470.

5. Chua KB (2003) Nipah virus outbreak in Malaysia. J Clin Virol 26: 265–275.

6. Dassak P, Ploswright R, Epstein JH, Plowright R, Abdul Rahman S, et al. (2006) The emergence of Nipah and Hendra virus: pathogen dynamics across a wildlife-livestock-human continuum. In: Collinge JS, editors. Disease ecology: community structure and pathogen dynamics. Oxford, United Kingdom: Oxford University Press. pp. 186–201.

7. Sharp PM, Hahn BH (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harbor Perspect Med 1: a006661.

8. Strelau M, Owens CM, Poon RT, Kiesling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM3alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848–853.

9. Sadler AJ, Williams BR (2007) Structure and function of the protein kinase R. Curr Top Microbiol Immunol 316: 253–292.

10. Mohr J, Petry T, Mathews MB (2007) Protein synthesis and translational control during viral infection. In: Mathews MB, Sonenberg N, Hershey JW, editors. Translational control in biology and medicine. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. pp. 345–399.

11. Daugerty MD, Malik HS (2012) Rules of engagement: molecular insights from the experiments: GB JOK APG. Analyzed the data: GB JOK JS APG. Conceived and designed the experiments: GB JOK SR JS APG. Performed research center genomic core and scientific imaging core for technical assistance.

12. Slabaugh MB, Roseman NA, Mathews CK (1989) Amplification of the ribonucleotide reductase small subunit gene: analysis of novel joints and the mechanism of gene duplication in vaccinia virus. Nucleic Acids Res 17: 7073–7081.

13. Child SJ, Berman G, Braggin JE, Geballe AP (2012) Species specificity of protein kinase r antagonism by cytomegalovirus TRS1 genes. J Virol 86: 3880–3889.

14. Garcia MA, Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89: 799–811.

15. Jones KE, Patel NG, Levy MA, Storey A, Balk D, et al. (2008) Global trends in emerging infectious diseases. Nature 451: 990–993.

16. Huygens CD, Condit RC (1992) Temperature-sensitive mutants in the vaccinia virus A11R gene increase double-stranded RNA synthesis as a result of aberrant viral transcription. Virology 194: 254–262.

17. Cressav SGD, Prins C, Latner DR, Condit RC (2007) Mapping and phenotypic analysis of spontaneous tafti-beta-thiocarbazonate resistant mutants of vaccinia virus. Virology 363: 319–332.

18. Rehn KE, Connor RF, Jones GJ, Yimbu K, Roper RL (2010) Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 397: 176–186.

19. Rehn KE, Roper RL (2011) Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching. Vaccine 29: 3276–3283.

20. Tallozcy Z, Jiang W, Virgin HW, Leib DA, Scheuner D, et al. (2002) Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci U S A 99: 190–195.

21. Rehn KE, Connor RF, Jones GJ, Yimbu K, Roper RL (2010) Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 397: 176–186.

22. Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89: 799–811.

23. Garcia MA, Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89: 799–811.

24. Rehm KE, Connor RF, Jones GJ, Yimbu K, Roper RL (2010) Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 397: 176–186.

25. Rehm KE, Roper RL (2011) Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching. Vaccine 29: 3276–3283.

26. Tallozcy Z, Jiang W, Virgin HW, Leib DA, Scheuner D, et al. (2002) Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci U S A 99: 190–195.

27. Rehm KE, Connor RF, Jones GJ, Yimbu K, Roper RL (2010) Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 397: 176–186.

28. Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89: 799–811.

29. Rehm KE, Connor RF, Jones GJ, Yimbu K, Roper RL (2010) Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology 397: 176–186.

30. Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89: 799–811.

31. Hett EC, Slater LH, Mark KG, Kawate T, Monks BG, et al. (2013) Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat Chem Biol 9: 398–405. nchembio.1236 [pii];10.1038/nchembio.1236 [doi].

32. Child SJ, HaRke M, De Niro KL, Geballe AP (2004) Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J Virol 78: 197–205.

33. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, et al. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 198: 217–232.

34. Beattie E, Paoletti E, Tartaglia J (1995) Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology 210: 254–263.

35. Beattie E, Tartaglia J, Paoletti E (1991) Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology 183: 419–422.

36. Rahman MM, Liu J, Chan WM, Rothenburg S, McFadden G (2013) Myxoma Virus Protein M929 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication. PLoS Pathog 9: e1003465.

37. Marshall EE, Bierle CJ, Brune W, Geballe AP (2009) Essential role for TRS1 or IRS1 in human cytomegalovirus replication. J Virol 83: 4112–4120.

38. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence alignment of the Clustal series of programs. Nucleic Acids Res 31: 396–401.

39. Espinosa J, Condit RC, Obijeski J (1980) The preparation of orthopoxvirus DNA. J Virol Methods 2: 175–179.

40. Simpson JT, Wong K, Jackman SD, Schein JE, Jones SJ, et al. (2009) ABYSS: a parallel assembler for short read sequence data. Genome Res 19: 1117–1123.

Table S3 Mutations identified in VV-A, VV-B and VV-C after four passages through HFF relative to vaccinia virus (strain Copenhagen).

(DOCX)

Table S4 Accession numbers.

(DOCX)

Acknowledgments

We thank Bertram Jacobs (Arizona State University) and Michael Axthelm (Oregon Health & Science University) for reagents. We thank members of the Geballe lab for helpful discussions and Harmit Malik (FHCRC), Matt Daugherty (FHCRC), and Nels Elde (University of Utah) for advice and critical reading of the manuscript. We thank the Fred Hutchinson Cancer Research Center Genomic Core and Scientific Imaging Core for technical assistance.

Author Contributions

Conceived and designed the experiments: GB JOK SR JS APG. Performed the experiments: GB JOK APG. Analyzed the data: GB JOK JS APG. Wrote the paper: GB JOK SR JS APG.
41. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760. btp324
42. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297–1303.
43. Li H, Durbin R (2010) Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589–595.
44. Kurtz S, Phillippy A, Delcher AL, Smoot M, Shumway M, et al. (2004) Versatile and open software for comparing large genomes. Genome Biol 5: R12. 10.1186/gb-2004-5-2-r12 [doi];gb-2004-5-2-r12 [pii].